As expected for any standalone software company, Parexel is deeply committed to IT, “eClinical technology solutions are fundamentally reshaping the biopharma landscape…being a successful CRO increasingly also means being an eCRO” (Investor Day), and this IT expertise confers benefits to the entire organization. But Parexel’s software platforms are a profit center themselves. Products include ClinPhone RTSM (randomization and trial supply management) – it has randomized 2.4m patients for 3,300 unique clinical trials – a medical imaging group that has processed 2.5m examinations, a clinical trials management system, IMPACT, utilized by nine of the top 20 pharma companies, and Liquent InSight for regulatory information management. Some of these were acquired, such as Liquent, and retain the non-PRXL brand name, allowing unrestricted usage by competitors. Parexel competes both with other CROs and with more traditional software companies like Medidata.
Parexel’s Consulting group, seen as an industry leader and staffed by former FDA officials, advises on a wide variety of projects, including regulatory outsourcing, pharmacovigilance, and post-approval commercialization. The Consulting segment competes with other CROs like Quintiles and inVentiv – all are positioned to extend customer relationships to before and after the clinical-stage.
Taken together, these segments are about 25% of revenue and 30% of PRXL’s gross profits. Hampered by a significant Consulting contract delay in 2014, a mix shift in Informatics away from commoditized services like medical imaging, and YTD FX headwinds, trailing growth for these segments has underwhelmed. In spite of this, Parexel’s LTM consolidated bookings of 1.3x suggests improvement through the coming year, as does recent management commentary:
FQ4 2015 Call
In our consulting business, declined project delays that we experienced earlier in the year were not fully resolved at the year-end. These projects are beginning to move forward now, in addition, in our new regulatory outsourcing business, client demand is increasing. These dynamics bode well for the business. As we expected in PAREXEL Informatics, revenue growth continues to roughly mirror that of CRS, reflecting the increasing levels of integration, between those businesses.
FQ 2016 Report
The first quarter represented a solid step forward for PAREXEL Consulting. A number of client projects that were delayed last year started moving forward, yielding improved profitability…PAREXEL Consulting revenue came in at $39.3 million, growing sequentially by 4.4% on a constant-currency basis…
In PAREXEL Informatics or PI, quarterly revenue was $62.6 million, representing a year-over-year decline of 2.1% on a constant-currency basis. We expect PAREXEL Informatics to return into positive revenue growth territory in our second quarter of fiscal year '16 as we expect a more favorable business mix… We believe the first quarter marked a low point in the revenue cycle for PI, and we anticipate improving financial performance in PI for the balance of fiscal year 2016, driven by margin leverage on sales growth as the business scales…
Over the next five years, management thinks regulatory outsourcing will grow at a 15% annual rate, nearly twice the rate of traditional outsourcing.